Literature DB >> 22073323

Subclinical Myocardial Dysfunction in Metabolic Syndrome Patients without Hypertension.

Jeong-Min Seo1, Tae-Ho Park, Dong-Yeol Lee, Young-Rak Cho, Hee-Kyung Baek, Jong-Seong Park, Moo-Hyun Kim, Young-Dae Kim, Sun-Young Choi, Sun-Mi Lee, Young-Seoub Hong.   

Abstract

BACKGROUND: The aim of this study was to evaluate myocardial function in patients with non-hypertensive metabolic syndrome.
METHODS: We selected metabolic syndrome patients (n = 42) without evidence of hypertension and compared them to age-matched control individuals (n = 20). All patients were evaluated by two-dimensional and tissue Doppler echocardiography including tissue Doppler derived strain and strain rate measurements.
RESULTS: There were no significant differences between the two groups in mitral E and A inflow velocities or the E/A ratio. However, systolic and early diastolic myocardial velocities, and strain rate were significantly lower in patients with metabolic syndrome than in the control group (all p < 0.05). Multiple stepwise regression analyses revealed that age, waist circumference, and systolic blood pressure were independently associated with peak systolic myocardial velocity.
CONCLUSION: These results indicate that metabolic syndrome patients without hypertension may have decrease of myocardial systolic and early diastolic velocities on tissue Doppler imaging, even if they appear to have normal systolic and diastolic function on conventional echocardiography.

Entities:  

Keywords:  Doppler echocardiography; Metabolic syndrome

Year:  2011        PMID: 22073323      PMCID: PMC3209592          DOI: 10.4250/jcu.2011.19.3.134

Source DB:  PubMed          Journal:  J Cardiovasc Ultrasound        ISSN: 1975-4612


Introduction

Metabolic syndrome (MS) is becoming a major health concern particularly in developed countries, with a prevalence of over 20% of the general adult population in the United States.1) Several studies from South Korea have reported that, as in Western countries, the prevalence of MS in the general adult population approximates 20%.2)3) MS is a known risk factor for the development of various cardiovascular diseases, including heart failure.4-8) Recent studies have shown that MS is directly related to relative left ventricular hypertrophy (LVH) and to systolic or diastolic dysfunction when assessed by two-dimensional or Doppler echocardiography.9-13) However, because in most of those studies, majority of patients had underlying diabetes mellitus (DM) or hypertension (HT), the influence of early MS on myocardial function has not been thoroughly evaluated. In addition, past studies have usually assessed diastolic function in MS patients by conventional Doppler echocardiography. Thus, we conducted this study to evaluate myocardial function in non-hypertensive MS patients by tissue Doppler Imaging (TDI) as well as conventional Doppler.

Methods

Study population

We screened subjects who visited the Healthcare Service Center of the Dong-A University Hospital. Complete cardiovascular examinations, including history taking, physical examination, and blood chemistry sampling, were performed in the outpatient clinic to screen for MS. Patients with known cardiovascular disease, HT, or stroke were excluded during the baseline examination. Weight, height, and waist circumference were obtained. Blood pressure (BP) was determined in the outpatient clinic using the conventional cuff method. Fasting serum glucose (FSG), total cholesterol, triglyceride (TG), high-density lipoprotein (HDL), and low-density lipoprotein levels were measured after fasting 12 hours overnight. For patients who were diagnosed with MS and agreed to participate in this study, signed informed consent was obtained, and comprehensive 2D and Doppler echocardiography were performed. We also selected control subjects who did not have MS. We applied the 2005 National Cholesterol Education Program (NCEP)/Adult Treatment Panel (ATP) III criteria to define MS. Subjects were diagnosed as having MS if they met three or more of the following criteria: waist circumference of ≥ 90 cm in men and ≥ 80 cm in women according to the NCEP/ATP III recommendations for the Asian population, TG level ≥ 150 mg/dL, serum HDL cholesterol level < 40 mg/dL in men and < 50 mg/dL in women, systolic blood pressure (SBP) ≥ 130 mmHg or diastolic blood pressure (DBP) ≥ 85 mmHg, and FSG level ≥ 100 mg/dL.14) However, patients with HT (systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg by the Joint National Committee 7th report criteria)15) or DM (FSG level ≥ 126 mg/dL by the American Diabetes Association)16) were excluded for the purpose of this study. Patients who had systolic dysfunction, cardiomyopathy, or significant valvular heart disease on 2D echocardiography were also excluded. Being overweight or obese was defined as having a body mass index (BMI) between 25-29.9 kg/m2 or ≥ 30 kg/m2, respectively, according to the World Health Organization criteria.17) For this study, impaired glucose metabolism was defined as a FSG level of 100-125.9 mg/dL. Finally, we selected 42 consecutive MS patients without HT and 20 age-matched control individuals without MS.

Echocardiography

Echocardiography was performed using the iE33 ultrasound system and 2.5 MHz transducers (Philips Ultrasound Company, Cleveland, OH, USA). Standard parasternal and apical views were acquired. Complete 2D and M-mode echocardiogram, conventional Doppler, and TDI were obtained for all enrolled individuals. We measured the following left ventricle (LV) parameters by M-mode echocardiography: interventricular septal wall thickness (IVS), posterior wall thickness (PW), and LV end diastolic dimension (EDD) at the chordae tendinae level. The LV mass was calculated according to the following equation: LV mass = 0.8 [1.04 × (PW + IVS + LVEDD)3 - (LVEDD)3] + 0.6.18) LV mass index was calculated as the LV mass divided by body surface area. LVH was defined as LV mass index ≥ 116 g/m2 for men and ≥ 104 for women.19) LV ejection fraction was measured by the modified Simpson method.20) Left atrial (LA) volumes were calculated using biplane Simpson method. LV diastolic function was evaluated by the measurements of early diastolic mitral inflow (E) velocity, late diastolic mitral inflow (A) velocity, E/A ratio, and mitral E wave deceleration time (DT) using conventional pulsed wave Doppler echocardiography. LV diastolic function was also estimated by TDI. Early diastolic mitral annular (Ea) velocity was measured by tissue Doppler placing sample volume at the lateral annulus.21) To obtain longitudinal myocardial velocity, strain rate, and strain images with high quality, a narrow sector angle was used, and image depth was adjusted to allow for a high frame rate (> 120 frames/s) with care taken to avoid angulations. The myocardial time-velocity and time-deformation curves were reconstructed off-line from color coded 2D tissue Doppler image loops. The peak systolic (Sm), early diastolic (Em), and late diastolic longitudinal myocardial velocities were measured at basal and mid segments of the septal, lateral, inferior, and anterior walls from apical 2- and 4-chamber views. Likewise, peak systolic (Ssr), early diastolic (Esr), late diastolic strain rate, and peak systolic strain (PSS) were measured at the same segments and expressed as absolute values. Their average values were used to compare regional and global LV functions of MS patients to those of control subjects. A single investigator who was blinded to clinical data performed echocardiographic measurements.

Statistical analyses

Statistical analyses were performed using the Statistical Package for Social Sciences version 12 (SPSS Inc., Chicago, IL, USA). Continuous values were presented as mean ± standard deviations. Group means were compared using independent t-tests. Proportional values of the two groups were compared using Pearson's Chi-Square test. Pearson's correlation analyses were performed to assess the associations between clinical parameters of MS (age, waist circumference, SBP, DBP, TG, HDL, and FSG) and echocardiographic parameters of myocardial function (tissue Doppler myocardial velocity, strain rate, and strain). Multiple stepwise regression analyses were performed to evaluate the influence of clinical factors on the differences in echocardiographic findings. A p-value of less than 0.05 was regarded as having statistical significance.

Results

Demographic and clinical characteristics of the study populations (metabolic and non-metabolic control groups) are summarized in Table 1. Age and gender distributions were similar in both groups. Although there was no significant difference in BMI, waist circumference was significantly larger in the MS than in the control group. Another remarkable variation was demonstrated in terms of BP and TG levels between the two groups. The FSG and HDL levels were not significantly different between the two groups. Thus, MS patients included in the present study had minimal risk factors for MS.
Table 1

Demographic and clinical characteristics

HDL: high-density lipoprotein, LDL: low-density lipoprotein, NS: not significant

M-mode, two-dimensional, and conventional doppler echocardiography

M-mode, 2D, and conventional Doppler echocardiographic measurements are shown in Table 2. LV size, LV mass, LA size, and LVEF were not significantly different between the two groups. LV diastolic function estimated by conventional Doppler criteria was similar in both groups. Thus, there were no significant differences in the prevalence of systolic and diastolic dysfunction when assessed by 2D and conventional Doppler echocardiography.
Table 2

Two-dimensional and pulsed wave Doppler echocardiography

LVEDD: left ventricular end-diastolic diameter, VS: left ventricular septal wall thickness, PW: left ventricular posterior wall thickness, LVM: left ventricular mass, LVMI: left ventricular mass index, LAV: left atrial volume, LAVI: left atrial volume index, LVEF: left ventricular ejection fraction, E: early diastolic transmitral inflow, A: late diastolic transmitral inflow, DT: mitral E wave deceleration time, NS: not significant

Tissue doppler imaging

Echocardiographic measurements by TDI are summarized in Table 3 and Fig. 1. Tissue Doppler velocities of the lateral annulus were 8.8 ± 2.4 and 11.8 ± 1.9 cm/s (p < 0.001) in the MS and control groups, respectively. Average values of Sm and Em measured at 8 myocardial segments were significantly lower in the MS group than in the control group (2.7 ± 0.4 vs. 4.0 ± 1.0 cm/s, p < 0.001; 4.0 ± 1.3 vs. 5.5 ± 1.4 cm/s, p = 0.008, respectively). In addition, average values of Ssr, Esr, and PSS were also significantly lower in the MS group than in the control group (1.1 ± 0.3 vs. 1.4 ± 0.3 s-1, p = 0.001; 1.2 ± 0.3 vs. 1.5 ± 0.3 s-1, p = 0.013; and 16.9 ± 3.7 vs. 20.5 ± 3.2%, p = 0.001, respectively).
Table 3

Myocardial velocities, strain rates, and peak systolic strain

Ea: peak mitral annular velocity during early diastole, Global Sm: the average of peak left ventricular systolic velocities, Global Em: the average of peak left ventricular early diastolic velocities, Global Am: the average of peak left ventricular late diastolic velocities, Global Ssr: the average of peak left ventricular systolic strain rates, Global Esr: the average of peak left ventricular early diastolic strain rates, Global Asr: the average of peak left ventricular late diastolic strain rates, Global PSS: the average of peak left ventricular systolic strain, NS: not significant

Fig. 1

Mean values of myocardial velocities and strain rate by tissue Doppler imaging in control and MS group. MS: metabolic syndrome, Sm: peak systolic, Em: early diastolic, Ssr: peak systolic, Esr: early diastolic.

Relationship of clinical and echocardiographic parameters

Linear regression analysis was performed to examine the relationship of echocardiographic measurements to clinical parameters in patients with MS and non-MS (Table 4). Age significantly correlated with all echocardiographic parameters representing myocardial function. Waist circumference, SBP, and FSG had significant correlations with two of five echocardiographic parameters. Among the echocardiographic parameters, Sm is the most representative paramenter which is able to evaluate myocardial dysfunction in MS in present study. A correlation index of Sm greater than 0.3 was seen in waist circumference and SBP.
Table 4

Correlation coefficients between clinical and echocardiographic parameters

*< 0.05, †< 0.01. WC: waist circumference, SBP: systolic blood pressure, DBP: diastolic blood pressure, FSG: fasting serum glucose, TG: triglyceride, HDL: high-density lipoprotein, Sm: peak systolic, Em: early diastolic, Ssr: peak systolic, Esr: early diastolic, PSS: peak systolic strain, E: early diastolic transmitral inflow, Ea: peak mitral annular velocity during early diastole

TG and HDL levels did not have significant correlations with any of the echocardiographic parameters. Stepwise multiple regression analysis was performed to examine the clinical parameters that influence global Sm (Table 5). The results indicated that age (β coefficient = -0.313, p = 0.006), waist circumference (β coefficient = -0.296, p = 0.012), and SBP (β coefficient = -0.253, p = 0.031) were independently associated with Sm.
Table 5

Multiple regression analyses to examine the clinical parameters that influence global Sm

Sm: peak systolic, WC: waist circumference, SBP: systolic blood pressure

Discussion

The results of our study showed that non-hypertensive MS patients had subclinical myocardial dysfunction that was made apparent by TDI. Previous studies have shown echocardiographic evidence of myocardial dysfunction in MS patients.11)12) However, most patients enrolled in those studies had overt DM or HT. Thus, diastolic dysfunction was evident by conventional parameters (E, A, and E/A) as well as TDI indices. In contrast, the present study shows that myocardial dysfunction in patients with an early stage of MS was detected by TDI not conventional parameters. We designed this study to test the hypothesis that early MS patients might have myocardial dysfunction. We excluded HT patients to estimate the true impact of early stage MS on myocardial function, which was the most important aspect of the present study. In addition, a study of MS patients without DM or HT lends itself to a better examination of the relationship between each metabolic parameter to myocardial function, because HT by itself is strong enough to cause a decline in diastolic function. Peak longitudinal myocardial velocities derived from pulsed wave TDI are useful indicators of global or regional LV dysfunction. The early diastolic TDI velocity of the mitral annulus is generally thought to be a preload independent index for LV relaxation, and it is used to estimate LV filling pressures.22)23) Strain and strain rate are other tools that can reflect myocardial function.24)25) We applied tissue Doppler myocardial velocity, strain, and strain rate together to detect subtle changes in global myocardial function. Conventional Doppler echocardiography revealed a tendency for MS patients to have more diastolic LV dysfunction. However, that tendency did not achieve statistical significance. In contrast, TDI studies showed significant differences that were not revealed by conventional pulsed wave Doppler studies. Lateral Ea velocity, Sm, Em, Ssr, Esr, and PSS were more profoundly decreased in the MS group compared to control, and the differences achieved statistical significance. The results of our study suggest that TDI is superior to a conventional pulsed wave Doppler study in detecting early myocardial dysfunction. The 34 patients with MS enrolled in our study were diagnosed by 3 criteria: waist circumference, low HDL levels, and high TG levels. Waist circumference reflects central obesity and risk of cardiovascular disease. Furthermore, it is considered to be the best predictor of MS among other diagnostic criteria.26) On the other hand, the direct influence of dyslipidemia on myocardial function is not well known. A recent study showed that short-term control of dyslipidemia using statin improved myocardial dysfunction assessed by the Tei index and tissue Doppler myocardial velocities. In that study, as in our current one, overt DM and HT patients were excluded; however, waist circumference was not measured. The results suggested that dyslipidemia itself may be a risk factor for myocardial dysfunction.27) In this study, we expected that waist circumference and lipid levels would exhibit good correlations with echocardiographic parameters because most MS patients were diagnosed by waist circumference and dyslipidemia. However, all metabolic parameters had a weak correlation with echocardiographic indices. Especially, dyslipidemia itself was not related to echocardiographic parameters, because the patients enrolled in this study had mild abnormalities of lipid profile. These data are different from previous study.27) Based on our results, age was the best parameter to predict myocardial dysfunction. Of the metabolic parameters, waist circumference and SBP were more important than FSG, TG and HDL in influencing myocardial dysfunction in patients with early MS. From multiple comparisons of echocardiographic and metabolic parameters, the highest correlation was observed between age and Em (r = -0.551, p < 0.001); however, metabolic parameters were more closely related to Sm than Em. The data in the present study indicate that waist circumference and SBP are independently associated with myocardial dysfunction (Sm). It is common knowledge that even a mild degree of diastolic dysfunction may be associated with poor prognosis on long-term follow-up;29) therefore, early detection of myocardial dysfunction may provide MS patients with a chance to modify their lifestyles, thereby preventing future heart disease. The use of TDI might detect early systolic and diastolic myocardial dysfunction in MS patients, even if they do not have overt DM, HT, or any structural abnormalities. There are a few limitations in present study. Firstly, the size of this study to assess the relationship of each MS factor with myocardial dysfunction was relatively small. Secondly, it is difficult to explain the exact pathophysiologic mechanisms of how early MS without overt HT influences myocardial function, although we postulate that insulin resistance that was not measured in this study might underlie decreased myocardial function. Thirdly, although all subjects in our study did not have any signs or symptoms of angina, and had normal findings on electrocardiogram and on 2-D echocardiography, we could not completely exclude asymptomatic coronary artery disease. In conclusion, these results indicate that patients with MS without HT may have myocardial dysfunction apparent by tissue Doppler imaging, even if they appear to have normal findings on two-dimensional and conventional Doppler studies.
  28 in total

1.  Analysis of the interaction between segmental relaxation patterns and global diastolic function by strain echocardiography.

Authors:  Yasuhiko Takemoto; Patricia A Pellikka; Jianwen Wang; Karen M Modesto; Sanderson Cauduro; Marek Belohlavek; James B Seward; Helen L Thomson; Bijoy Khandheria; Theodore P Abraham
Journal:  J Am Soc Echocardiogr       Date:  2005-09       Impact factor: 5.251

2.  Myocardial and vascular dysfunction and exercise capacity in the metabolic syndrome.

Authors:  Chiew Y Wong; Trisha O'Moore-Sullivan; Zhi Y Fang; Brian Haluska; Rodel Leano; Thomas H Marwick
Journal:  Am J Cardiol       Date:  2005-10-26       Impact factor: 2.778

3.  Tissue Doppler imaging for the detection and quantitation of myocardial dysfunction in patients with type 2 diabetes mellitus.

Authors:  Helene Von Bibra; Inga S Thrainsdottir; Alexander Hansen; Vasilios Dounis; Klas Malmberg; Lars Rydén
Journal:  Diab Vasc Dis Res       Date:  2005-02       Impact factor: 3.291

4.  Obesity: preventing and managing the global epidemic. Report of a WHO consultation.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  2000

5.  Cardiovascular morbidity and mortality associated with the metabolic syndrome.

Authors:  B Isomaa; P Almgren; T Tuomi; B Forsén; K Lahti; M Nissén; M R Taskinen; L Groop
Journal:  Diabetes Care       Date:  2001-04       Impact factor: 19.112

6.  Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.

Authors:  Earl S Ford; Wayne H Giles; William H Dietz
Journal:  JAMA       Date:  2002-01-16       Impact factor: 56.272

7.  Metabolic syndrome is associated with abnormal left ventricular diastolic function independent of left ventricular mass.

Authors:  Lisa de las Fuentes; Angela L Brown; Santhosh J Mathews; Alan D Waggoner; Pablo F Soto; Robert J Gropler; Víctor G Dávila-Román
Journal:  Eur Heart J       Date:  2007-02-20       Impact factor: 29.983

8.  Metabolic syndrome and left ventricular hypertrophy in the prediction of cardiovascular events: the Strong Heart Study.

Authors:  G de Simone; R B Devereux; M Chinali; M J Roman; E T Lee; H E Resnick; B V Howard
Journal:  Nutr Metab Cardiovasc Dis       Date:  2008-07-31       Impact factor: 4.222

9.  The prevalence of the metabolic syndrome in Korean adults: comparison of WHO and NCEP criteria.

Authors:  Sung Hee Choi; Chul Woo Ahn; Bong Soo Cha; Yoon-Sok Chung; Kwan Woo Lee; Hyun Chul Lee; Kap Bum Huh; Dae Jung Kim
Journal:  Yonsei Med J       Date:  2005-04-30       Impact factor: 2.759

10.  Acute effect of nonsurgical septal reduction therapy on regional left ventricular asynchrony in patients with hypertrophic obstructive cardiomyopathy.

Authors:  Tae-Ho Park; Nasser M Lakkis; Katherine J Middleton; Jennifer Franklin; William A Zoghbi; Miguel A Quiñones; William H Spencer; Sherif F Nagueh
Journal:  Circulation       Date:  2002-07-23       Impact factor: 29.690

View more
  9 in total

1.  Association Between Subclinical Left Ventricular Myocardial Systolic Dysfunction Detected by Strain and Strain‑Rate Imaging and Liver Steatosis and Fibrosis Detected by Elastography and Controlled Attenuation Parameter in Patients with Metabolic Syndrome.

Authors:  Andrei Vitel; Diana-Aurora Bordejevic; Ioan Sporea; Ruxandra Mare; Christian Banciu; Tudor Parvanescu; Ioana Mihaela Citu; Mirela Cleopatra Tomescu
Journal:  Diabetes Metab Syndr Obes       Date:  2020-10-15       Impact factor: 3.168

2.  Increased H-FABP concentrations in nonalcoholic fatty liver disease. Possible marker for subclinical myocardial damage and subclinical atherosclerosis.

Authors:  O Başar; E Akbal; S Köklü; Y Tuna; E Koçak; N Başar; D Tok; H Erbiş; M Senes
Journal:  Herz       Date:  2013-01-18       Impact factor: 1.443

3.  Metabolically healthy and unhealthy obesity: differential effects on myocardial function according to metabolic syndrome, rather than obesity.

Authors:  R Dobson; M I Burgess; V S Sprung; A Irwin; M Hamer; J Jones; C Daousi; V Adams; G J Kemp; F Shojaee-Moradie; M Umpleby; D J Cuthbertson
Journal:  Int J Obes (Lond)       Date:  2015-08-14       Impact factor: 5.095

4.  Right ventricle free wall mechanics in metabolic syndrome without type-2 diabetes: effects of a 3-month lifestyle intervention program.

Authors:  Juan Serrano-Ferrer; Guillaume Walther; Edward Crendal; Agnès Vinet; Frédéric Dutheil; Geraldine Naughton; Bruno Lesourd; Robert Chapier; Daniel Courteix; Philippe Obert
Journal:  Cardiovasc Diabetol       Date:  2014-08-03       Impact factor: 9.951

5.  Diastolic dysfunction in the diabetic continuum: association with insulin resistance, metabolic syndrome and type 2 diabetes.

Authors:  Ricardo Fontes-Carvalho; Ricardo Ladeiras-Lopes; Paulo Bettencourt; Adelino Leite-Moreira; Ana Azevedo
Journal:  Cardiovasc Diabetol       Date:  2015-01-13       Impact factor: 9.951

6.  Early detection of regional and global left ventricular myocardial function using strain and strain-rate imaging in patients with metabolic syndrome.

Authors:  Qin Wang; Qi-Wei Sun; Dan Wu; Ming-Wu Yang; Rong-Juan Li; Bo Jiang; Jiao Yang; Zhi-An Li; Ying Wang; Ya Yang
Journal:  Chin Med J (Engl)       Date:  2015-01-20       Impact factor: 2.628

7.  Genistein Supplementation and Cardiac Function in Postmenopausal Women with Metabolic Syndrome: Results from a Pilot Strain-Echo Study.

Authors:  Cesare De Gregorio; Herbert Marini; Angela Alibrandi; Antonino Di Benedetto; Alessandra Bitto; Elena Bianca Adamo; Domenica Altavilla; Concetta Irace; Giacoma Di Vieste; Diego Pancaldo; Roberta Granese; Marco Atteritano; Salvatore Corrao; Giuseppe Licata; Francesco Squadrito; Vincenzo Arcoraci
Journal:  Nutrients       Date:  2017-06-07       Impact factor: 5.717

8.  Significant Association Between Left Ventricular Diastolic Dysfunction, Left Atrial Performance and Liver Stiffness in Patients with Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease.

Authors:  Tudor Parvanescu; Andrei Vitel; Ioan Sporea; Ruxandra Mare; Bogdan Buz; Diana Aurora Bordejevic; Mirela Cleopatra Tomescu; Sergiu Florin Arnautu; Vlad Ioan Morariu; Ioana Mihaela Citu
Journal:  Diabetes Metab Syndr Obes       Date:  2021-04-09       Impact factor: 3.168

9.  Relationship between Metabolic Syndrome and Ocular Microcirculation Shown by Laser Speckle Flowgraphy in a Hospital Setting Devoted to Sleep Apnea Syndrome Diagnostics.

Authors:  Tomoaki Shiba; Mao Takahashi; Tadashi Matsumoto; Yuichi Hori
Journal:  J Diabetes Res       Date:  2017-09-05       Impact factor: 4.011

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.